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oRIgInaL REsEaRCh REpoRts
Mechanism of paroxysmal nocturnal 
hemoglobinuria clonal dominance: possible roles 
of different apoptosis and CD8+lymphocytes in the 
selection of paroxysmal nocturnal hemoglobinuria 
clones 
Kunyaboon and colleagues from Siriraj Hospital in Bangkok de-
tected increased apoptosis in glycosylphosphatidylinositol+ cells 
that was likely responsible for selection and expansion of PNH 
clones. Mononuclear cells may play a role in this phenomenon.
     
Clinical outcome of docetaxel in advanced or 
metastatic endometrial cancer 
In a phase II study, Hamed and Abdelkhalek of Mansoura 
University in Egypt found that docetaxel was as effective as first-
line therapy in 50 patients with endometrial cancer and that tox-
icity was manageable and predominantly hematologic.
     
Addition of amifostine to the CHOP regimen in 
elderly patients with aggressive non-Hodgkin 
lymphoma: a phase II trial showing reduction in 
toxicity without altering long-term survival
Gómez and colleagues of Oncosalud in Lima, Perú, found that 
the addition of amifosine to CHOP reduced toxicity without al-
tering 8-year time-to-progressive, disease-free survival, or overall 
survival in patients older than 69 years of age. The International 
Prognostic Index was the only predictor of prognosis.  
The effect of low altitude on blood count parameters 
In a cross-sectional study, Al-Seedan and Alhaj of King Abdullah 
University Hospital, Amman, Jordan, found that hematological 
values of people living near the Dead Sea at an alititude 200 to 
300 meters below sea level differed significantly from those of 
people living 500 to 1500 meters above sea level.
 
CasE REpoRt
Allogeneic stem cell transplantation for acute 
myeloid leukemia with del(7q) following untreated 
chronic lymphocytic leukemia 
DeFilipp and colleagues at the West Penn Allegheny Health 
System in Pittsburgh present a rare case of de novo del(7) AML 
occurring in a patient with CML. CLL had no detrimental effect 
on treatment or transplant outcome. Over a year after transplan-
tation, the patient remained in complete hematologic and cytoge-
netic remission.
